Platinib treatment cycle and key usage guidelines

Platinib, as a targeted drug specifically targetingRET fusion-positive and RET-mutant tumors, its treatment duration and usage specifications are extremely critical for patients and doctors. Regarding the duration of platinib treatment, it is generally recommended that patients continue treatment until the disease does not progress or unbearable adverse reactions occur. This recommendation is based on the drug's durable anti-tumor activity demonstrated in clinical trials and considerations for optimal patient outcomes.

While taking Platinib, patients should pay attention to the following key matters:

1. Drug dosage and duration: Patients should strictly follow the instructions of the medical team to take the medication, and are not allowed to change the dosage or stop the medication without authorization. The dosage and cycle of Platinib are based on the patient's individual condition and disease progression, and any self-adjustment may adversely affect the efficacy.

2. Adverse reaction response: During treatment with Platinib, patients may experience discomfort such as nausea, vomiting or diarrhea. Once these symptoms occur, patients should immediately report back to the medical team so that the doctor can make corresponding adjustments based on the actual situation, such as adjusting the dosage, temporarily or permanently discontinuing the medication.

3. How to take the drug: To ensure effective absorption of the drug, Platinib should be taken on an empty stomach, that is, at least 2 hours before taking the drug and at least 1 hour after taking the drug and food should be avoided.

4. Countermeasures for missed doses: If the patient accidentally misses a dose of platinib, he should take it as soon as possible and within the same day. Then resume your normal dosing schedule the next day to maintain treatment continuity.

5. Drug storage: Platinib should be stored in an environment of 20°C to 25°C, allowed to fluctuate within the range of 15°C to 30°C, and should be kept dry to ensure the stability and effectiveness of the drug.

In summary, it is recommended that patients continue to use Platinib until their condition changes or intolerance occurs. During the entire treatment process, patients should strictly follow the doctor's instructions and pay careful attention to drug dosage, taking methods, adverse reaction handling and storage requirements to ensure the effectiveness of treatment and personal safety.